HER2 Support Group Forums - View Single Post - T-DM1 data at San Antonio

schoonder · 11-25-2009, 03:06 PM

Ellie,

At SABCS on 12-12-09 Genentech has a poster presentation(#5090) that displays results obtained from the phaseII T-DM1 trial that was fully enrolled (~100 participants) last February.
5090
A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody-Drug Conjugate, in Patients Previously Treated with Lapatinib, Trastuzumab, and Chemotherapy
Krop I, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Agresta S, Zheng M, Amler L, Rugo H. Dana Farber Cancer Institute, Boston, MA; Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin-Bren Simon, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Sarah Cannon Research Institute, Nashville, TN; South Texas Oncology/Hematology, San Antonio, TX; Genentech, South San Francisco, CA; UCSF Comprehensive Cancer Center, San Francisco, CA.

11-25-2009, 03:06 PM	#2
schoonder Senior Member Join Date: Jul 2008 Posts: 186	Re: T-DM1 data at ASCO Ellie, At SABCS on 12-12-09 Genentech has a poster presentation(#5090) that displays results obtained from the phaseII T-DM1 trial that was fully enrolled (~100 participants) last February. 5090 A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody-Drug Conjugate, in Patients Previously Treated with Lapatinib, Trastuzumab, and Chemotherapy Krop I, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Agresta S, Zheng M, Amler L, Rugo H. Dana Farber Cancer Institute, Boston, MA; Karmanos Cancer Institute, Detroit, MI; Indiana University Melvin-Bren Simon, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Sarah Cannon Research Institute, Nashville, TN; South Texas Oncology/Hematology, San Antonio, TX; Genentech, South San Francisco, CA; UCSF Comprehensive Cancer Center, San Francisco, CA.